A study published in Nature Biotechnology describes an engineered UGA‑suppressor tRNA gene designed to broaden the targets addressable by AAV-delivered therapies. The suppressor tRNA enables readthrough of UGA stop codons to restore full-length protein expression across different genetic contexts, offering a disease-agnostic mechanism to expand AAV payload utility. Authors present in vivo data supporting the approach and discuss implications for vector design, payload size and translational safety testing. Developers of AAV therapeutics may leverage this tool to target previously intractable truncating mutations.